{
  "docId": "019de073-7b6a-72bb-8d98-812d56d63617",
  "docSlug": "f8b2787992eb3375620f74057447d0c9",
  "documentTitle": "Aravive | Investor Presentation Deck | 39 slides",
  "authorId": "aravive",
  "authorName": "Aravive",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2022-09-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 4,
  "pageCount": 39,
  "prevPage": 3,
  "nextPage": 5,
  "slideType": "problem_statement",
  "function": "frame_problem",
  "density": "dense",
  "nDataPoints": 12,
  "notes": "The slide uses academic citations to establish the clinical relevance of the target protein.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de073-7b6a-72bb-8d98-812d56d63617/4",
  "deckHref": "/decks/019de073-7b6a-72bb-8d98-812d56d63617",
  "deckJsonHref": "/decks/019de073-7b6a-72bb-8d98-812d56d63617.json",
  "deckAnchorHref": "/decks/019de073-7b6a-72bb-8d98-812d56d63617#slide-4",
  "components": [
    {
      "bbox": {
        "h": 0.15,
        "w": 0.25,
        "x": 0.02,
        "y": 0.25
      },
      "kind": "paragraph",
      "text": "AXL expressed in ≥70% of ovarian, pancreatic, breast, kidney, and uterine cancers*",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "46ec157d-0f4f-4009-a1f3-de0e64e12185",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.25,
        "x": 0.02,
        "y": 0.45
      },
      "kind": "quote",
      "text": "Clinically, the expression of GAS6 and TAM receptors always predicts poor prognosis",
      "attrs": null,
      "subkind": "pull-quote",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "6208bd20-5593-49f3-bc82-7d0155bf56b5",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.4,
        "x": 0.58,
        "y": 0.88
      },
      "kind": "source-note",
      "text": "The Cancer Genome Atlas (TCGA), Axelrod and Pienta (AXL Review); Oncotarget, 2014 Oct; 5(19): 8818-8852; Miao et al (AXL Review) 2017, Drug Target Review Article 22309.",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "7b5563d9-a578-4225-9384-2eda94a26e36",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.7,
        "w": 0.7,
        "x": 0.28,
        "y": 0.15
      },
      "kind": "table",
      "text": "Tumor Type, AXL Tumor Expression, Publications & Data",
      "attrs": null,
      "subkind": "data",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "6e245a48-0af8-436a-ba3f-c436148085f2",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.9,
        "x": 0.02,
        "y": 0.02
      },
      "kind": "title",
      "text": "GAS6 & AXL Expression Associated with Poor Survival in Many Cancers",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "98c422cc-4896-4d80-be9a-7f2b5894b4cd",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [
    {
      "name": "authority-citation",
      "slug": null,
      "matchId": "3bb803db-4092-4f69-8eeb-d5436bb40d81",
      "evidence": "Uses academic citations to validate the clinical problem statement.",
      "confidence": 0.9
    }
  ],
  "arcBeats": [
    {
      "to": 6,
      "from": 4,
      "beatId": "28f3f743-e3cf-4d52-acd4-476055b1969c",
      "arcName": "Problem-Agitate-Solution",
      "arcSlug": "problem-agitate-solution",
      "beatName": "Problem (Identify pain)",
      "beatSlug": "problem-agitate-solution-problem-identify-pain",
      "evidence": "Slides 4-6 highlight the problems associated with GAS6/AXL signaling and the need for effective treatment",
      "position": 0,
      "confidence": 0.8,
      "parentBeatName": "Complication",
      "parentBeatSlug": "complication"
    }
  ],
  "loops": [
    {
      "to": 6,
      "from": 4,
      "name": "Cost Of Inaction",
      "slug": "27-cost-of-inaction",
      "bestFor": "Urgent budget requests, compliance, risk mitigation",
      "matchId": "2bad4849-76ce-484b-ad2f-532281679f0e",
      "evidence": "The document highlights the limitations of current treatments and the potential benefits of targeting GAS6/AXL signaling",
      "position": 0,
      "objective": "What is the cost of not addressing GAS6/AXL signaling in cancer treatment?",
      "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
      "confidence": 0.6,
      "description": "Quantify what happens if the audience does nothing"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}